PATIENT ASSISTANCE PROGRAMS

Size: px
Start display at page:

Download "PATIENT ASSISTANCE PROGRAMS"

Transcription

1 PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed for approved indications only. Completion of Class II Approval Form is necessary. In addition, where indicated, approval from Tumour Group Chair or delegate is required for reimbursement Reimbursement for approved indications only. Completion of the Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to provide the appropriate clinical information for each patient The Patient Assistance Program chart is a general reference on the available programs offered by pharmaceutical manufacturers to help patients access specific drug therapies. Inclusion in the chart does not imply BC Cancer Agency endorsement of any drug therapy that is not approved on the BC Cancer Agency Benefit Drug List. Care has been taken to ensure accuracy of information; however it is not intended to replace specific information as provided by the manufacturer. Since program requirements are constantly evolving, it is advised that this chart not be used as a sole source of information. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 1/32

2 Home injection programs DRUG SUPPLIER CLASS PROGRAM INFORMATION Buserelin (SUPREFACT ) Degarelix (FIRMAGON ) Goserelin (ZOLADEX ) Sanofi-Aventis Class I SUPREFACT Home Injection Program Medicum Patient Assistance Program Tel: Fax: Home delivery (weigh bills provided to pharmacies to ship buserelin and charge to the SUPREFACT Community Care and Home Injection Program) Home injection service (free of charge) Ferring Class I Coverdale Clinics - Firmagon Injection Program Tel: Fax: Ten fully operational clinics across BC Physician enrolls patient on the program for administration at a nearby clinic. TerSera Class I ZOLADEX Community Care and Home Injection Program Tel: Fax: Home Injection Program (free of charge) H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 2/32

3 DRUG SUPPLIER CLASS PROGRAM INFORMATION Lanreotide (SOMATULINE ) Leuprolide (ELIGARD ) Leuprolide (LUPRON ) Ipsen Class I or based on indication IPSEN CARES Program Tel: Fax: Financial assistance is available to all patients with or without third party insurance Compassionate supply available, based on financial need Home delivery service available Home injection service (free of charge) Sanofi-Aventis Class I ELIGARD Home Injection Program Tel: Fax: Home delivery (waybills provided to pharmacies to ship leuprolide and charge to the ELIGARD Community Care and Home Injection Program) Home injection service (free of charge) AbbVie Class I LupronCares Support Program Tel: Fax: Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) Home delivery (pre-paid waybills provided to pharmacies to ship leuprolide to patient s home if they are immobile or live in rural areas) H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 3/32

4 DRUG SUPPLIER CLASS PROGRAM INFORMATION Octreotide (SANDOSTATIN ) Novartis Pharmaceuticals Class I Access SANDOSTATIN LAR Tel: Fax: Help for patients to obtain third party coverage Financial assistance may be provided Home injection service (free of charge) H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 4/32

5 Supportive care medications DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Aprepitant (EMEND ) Merck PharmaCare Special Authority required. Dalteparin (FRAGMIN ) Pfizer Funded by for approved indications for inpatient use only. Funded by for approved indications for inpatient use only. Merck Canada Patient Assistance Program Tel: Fax: Compassionate supply is available to patients without third party insurance coverage Once certain criteria are met (i.e. proof of low income) medication is delivered to prescriber s office or to a designated pharmacy to dispense and for patient pick up Fragmin First Dose Program Tel: Fax: Sample card allows for: o treatment doses (5 free syringes) o prophylactic doses (10 free syringes) Fragmin Patient Assistance Card: o Financial assistance is available to all patients who have third party insurance coverage but may need help with the co-pay PharmaCare Special Authority required. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 5/32

6 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Darbepoetin (ARANESP ) Amgen VICTORY Program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the co-pay Darbepoetin will be shipped by Victory program to a designated pharmacy Program to be initiated before patient goes to Not required Eltrombopag (REVOLADE ) Novartis pharmacy inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to co-pay based on household income. PharmaCare Special Authority required. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 6/32

7 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Epoetin Alfa (EPREX ) Janssen SPECTRUM Support Program for Eprex Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the co-pay A compassionate supply is available to patients without third party insurance coverage, based on financial needs SPECTRUM program coordinates delivery with patients preferred pharmacy Initial self injection training with Nurse available in most regions. SPECTRUM program Not required Filgrastim (GRASTOFIL ) Apotex Funded by for approved indications for inpatient use only. will coordinate nurse home visit with patient Apobiologix ANSWERS Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance coverage Co-pay assistance available Program needs to be initiated and PharmaCare approval established before patient goes to the pharmacy PharmaCare Special Authority required. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 7/32

8 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Filgrastim (NEUPOGEN ) Amgen PharmaCare Special Authority required. Pegfilgrastim (NEULASTA ) Amgen Funded by for approved indications for inpatient use only. VICTORY Program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the co-pay Victory Program will assist with the co-pay based on financial need and Fair PharmaCare deductible for each patient Program needs to be initiated and PharmaCare approval established before patient goes to the pharmacy VICTORY Program Tel: Fax: Financial assistance is available to all patients who have third party insurance coverage but may need help with the co-pay Compassionate supply will be shipped by Victory program to a designated pharmacy If patient is prescribed NEULASTA and has no third party coverage, they will be offered NEUPOGEN Program to be initiated before patient goes to pharmacy Not required H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 8/32

9 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Posaconazole (POSANOL ) Merck Canada Merck Care Oncology Tel: Fax: Financial assistance is available to eligible patients with third party insurance coverage but may need help with the co-pay Not required Valacyclovir (VALTREX ) GlaxoSmithKline Compassionate supply available VALTREX Patient Assist Program Tel: Web: The VALTREX Patient Assist Program will cover up to the difference between the out of pocket amount of branded VALTREX (valacyclovir hydrochloride) versus the out of pocket amount a patient would have paid based on the average generic drug price. This amount will vary depending on each patient s coverage (i.e., public, private, none) in each province. Patients must first have their prescription filled at a community pharmacy and have the receipt when they call the program Not required H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 9/32

10 DRUG SUPPLIER CLASS PROGRAM INFORMATION PHARMACARE SPECIAL AUTHORITY Vorinostat (ZOLINZA ) Merck Canada Merck Care Oncology Tel: Fax: Financial assistance is available to eligible patients with third party insurance coverage but may need help with the co-pay Compassionate supply available Not required H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 10/32

11 Drugs with assistance/reimbursement programs and/or coordination of insurance coverage DRUG SUPPLIER CLASS PROGRAM INFORMATION Abiraterone (ZYTIGA ) Afatinib (GIOTRIF ) Alectinib (ALECENSARO ) Janssen Boehringer Ingelheim Roche Janssen BioAdvance ZYTIGA Drug Access and Patient Support Program Tel: zytiga@bioadvanc .ca Financial assistance is available to all patients with or without third party insurance No compassionate supply available Home delivery available Home delivery of one blood pressure monitor per patient available Scheduling of monitoring services at a local clinic or patient s home (if applicable) HeadStart Patient Assistance Program Tel: Fax: Financial assistance is available to all patients with or without third party insurance Compassionate supply available Home delivery available through HeadStart Program Program information can be found at: Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with third party H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 11/32

12 DRUG SUPPLIER CLASS PROGRAM INFORMATION Alemtuzumab (CAMPATH ) Anastrozole (TEVA brand) Atezolizumab (TECENTRIQ ) Axitinib (INLYTA ) Bevacizumab (AVASTIN ) Genzyme Class I Clinigen Group Tel: Fax: Teva Class I TEVA Compassionate Care Program Tel: Compassionate access is available to eligible patients Application form is to be sent by mail or courier, and must be Roche Pfizer Roche Class I or based on indication accompanied by original prescription Roche Patient Assistance Program (RPAP) Tel: Fax: This bridging program will provide financial assistance to eligible patients, on a case-by-case basis Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance may be available on a case-by-case basis Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with third party Infusion coordination provided if required H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 12/32

13 DRUG SUPPLIER CLASS PROGRAM INFORMATION Bendamustine (TREANDA ) Bosutinib (BOSULIF ) Lundbeck Pfizer TREANDA Patient Support Program Tel: Fax: No compassionate supply available Infusion coordination provided if required Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance may be available on a case-by-case basis Cabazitaxel (JEVTANA ) Capecitabine (TEVA brand) Sanofi Teva Class I or based on indication Sanofi Cancer Patient Assistance Program Tel: SANOFI Fax: TEVA Compassionate Care Program Tel: Compassionate access is available to eligible patients Application form is to be sent by mail or courier, and must be accompanied by original prescription H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 13/32

14 DRUG SUPPLIER CLASS PROGRAM INFORMATION Carfilzomib (KYPROLIS ) Amgen VICTORY Program Tel: Fax: insurance coverage but may need help with co-pay Compassionate supply available Ceritinib (ZYKADIA ) Cobimetinib (COTELLIC ) Novartis Roche My Lungs Program Tel: Fax: Patients who were previously enrolled in the compassionate use program will get financial assistance with no limit. New patients will get 20% financial assistance. Home delivery available through McKesson Pharmacy Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with or without third party insurance Bridging program ceases November 11, 2017 H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 14/32

15 DRUG SUPPLIER CLASS PROGRAM INFORMATION Crizotinib (XALKORI ) Pfizer Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance may be available on a case-by-case basis Dabrafenib (TAFINLAR ) Daratumumab (DARZALEX ) GlaxoSmithKline Janssen inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to co-pay based on household income. Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy Janssen BioAdvance DARZALEX Drug Access and Patient Support Program Tel: darzalex@bioadvanc .ca Financial assistance is available to patients with third party insurance Some financial assistance may be available to patients without third party insurance No compassionate supply available Private infusion clinic availability H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 15/32

16 DRUG SUPPLIER CLASS PROGRAM INFORMATION Dasatinib (SPRYCEL ) Denosumab (XGEVA ) Doxorubicinpegylated liposomal (CAELYX ) BMS Amgen Access to Hope Program Tel: Fax: Financial assistance and compassionate supply available to all patients with or without third party insurance coverage on a case-by-case evaluation VICTORY Program Tel: Fax: Janssen Class I Richard K. Plante, Director of Oncology, Janssen Tel: Mobile: rplante@its.jnj.com Durvalumab (IMFINZI ) AstraZeneca or Myrna O Brodovich, Medical Information, Janssen Tel: medinfocanada@joica.jnj.com AstraZeneca Oncology Patient Support Program Tel: Fax: Health Canada approved indication only Financial assistance available based on financial need and availability of third party insurance coverage Coordination with private infusion clinic H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 16/32

17 DRUG SUPPLIER CLASS PROGRAM INFORMATION Enzalutamide (XTANDI ) Eribulin (HALAVEN ) Erlotinib (TARCEVA ) Astellas Eisai Roche Class I or based on indication XTANDI Patient Assistance Program Tel: Fax: Financial assistance is available to all patients with or without third party insurance Home delivery available through McKesson Pharmacy Eisai Assistance Program Tel: Fax: No compassionate supply available Infusion coordination provided if required Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance and RPAP services end March 31, 2015 InnoviCares - Tarceva benefit card: Program covers up to the difference in the drug ingredient cost between Tarceva and the respective generic alternatives Benefit card can be downloaded from H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 17/32

18 DRUG SUPPLIER CLASS PROGRAM INFORMATION Everolimus (AFINITOR ) Exemestane (TEVA brand) Fulvestrant (FASLODEX ) Novartis Class I or based on indication AfiniTRAC Reimbursement Support Program Tel : Fax : Teva Class I TEVA Compassionate Care Program Tel: Compassionate access is available to eligible patients Application form is to be sent by mail or courier, and must be accompanied by original prescription AstraZeneca Patient Assistance Program Tel: Fax: enrollment@azoncologypsp.ca Compassionate supply available for eligible patients (non-visceral metastatic ER+/HER2- without prior endocrine therapy) Starting January 2018, new patients not meeting above criteria will be eligible for up to 20% in financial assistance with the innovicares benefit card, available at H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 18/32

19 DRUG SUPPLIER CLASS PROGRAM INFORMATION Ibrutinib (IMBRUVICA ) Idelalisib (ZYDELIG ) Imatinib (GLEEVEC ) Imatinib (TEVA brand) Janssen Gilead Novartis Teva Class I or based on indication Class I or based on indication Janssen BioAdvance IMBRUVICA Drug Access and Patient Support Program Tel: imbruvica@bioadvanc .ca Financial assistance is available to all patients with or without third party insurance Compassionate drug access may be available Home delivery available Drug Access Special Assistance (DASA) for previously untreated patients with CLL program ending upon provincial reimbursement Gilead Oncology Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance Compassionate supply may be available GIST Alliance Tel: Fax: Program covers up to 20% of drug cost TEVA Compassionate Care Program Tel: Compassionate access is available to eligible patients Application form is to be sent by mail or courier, and must be accompanied by original prescription H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 19/32

20 DRUG SUPPLIER CLASS PROGRAM INFORMATION Interferon alpha (INTRON A ) Ipilimumab (YERVOY ) Irinotecan liposome (ONIVYDE ) Ixazomib (NINLARO ) Merck Class I Merck Care TM Oncology Tel: Fax: BMS Baxalta / Shire Takeda Canada ACCESS TO HOPE Program Tel: Fax: % co-pay assistance available to all patients Reimbursement navigation Infusion clinic coordination onward patient support program Tel: Fax: Compassionate supply available NINLARO Compassionate Access Program Tel: Fax: ninlaro.canada@takeda.com Compassionate supply available on a case-by-case assessment Tel/Fax/ to obtain Compassionate Access Request Form. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 20/32

21 DRUG SUPPLIER CLASS PROGRAM INFORMATION Lapatinib (TYKERB ) Lenalidomide (REVLIMID ) Lenvatinib (LENVIMA ) Letrozole (FEMARA ) GlaxoSmithKline Celgene Eisai inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to co-pay based on household income RevAid program Tel: Fax: Web: Financial assistance is available to all patients with or without third party insurance coverage Compassionate supply may be available for non- funded indications EISAI CARES Patient Support Program Tel: Fax: Novartis Class I Access FEMARA Tel: Fax: Compassionate supply of FEMARA available based on financial need H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 21/32

22 DRUG SUPPLIER CLASS PROGRAM INFORMATION Letrozole (TEVA brand) Nilotinib (TASIGNA ) Nivolumab (OPDIVO ) Teva Class I TEVA Compassionate Care Program Tel: Compassionate access is available to eligible patients Application form is to be sent by mail or courier, and must be accompanied by original prescription Novartis BMS The Alliance Patient Support Program Tel: Fax: ACCESS TO HOPE Program Tel: Fax: % co-pay assistance available to all patients (monotherapy) Reimbursement navigation Infusion clinic coordination Melody Program Compassionate supply to be administered at BC Cancer centres (combination therapy with ipilimumab in treatment-naïve melanoma) Program enrolment ends May 2018 H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 22/32

23 DRUG SUPPLIER CLASS PROGRAM INFORMATION Obinutuzumab (GAZYVA ) Olaparib (LYNPARZA ) Osimertinib (TAGRISSO ) Roche AstraZeneca AstraZeneca Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to patients who have third party, on a case-bycase basis AstraZeneca Oncology Patient Support Program Tel: Fax: Compassionate supply available for patients without third party insurance (Health Canada approved indication only) AstraZeneca Oncology Patient Support Program Tel: Fax: Compassionate supply available H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 23/32

24 DRUG SUPPLIER CLASS PROGRAM INFORMATION Paclitaxel-nab (ABRAXANE ) Palbociclib (IBRANCE ) Panitumumab (VECTIBIX ) Celgene Class I ABRAXANE Access Program Tel: Fax: Financial assistance is available for non- funded indications o For patients who have third party insurance coverage but may need help with the co-pay o Reduced cost Cash pay option for patients with no insurance coverage Compassionate supply NO LONGER AVAILABLE Infusion coordination and/or shipping to private infusion clinic or hospital pharmacy Pfizer Amgen Class I or based on indication Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance is available to eligible patients with third party insurance coverage who need help with the co-pay Compassionate supply is no longer available VICTORY Program Tel: Fax: Financial assistance available to patients without third party insurance coverage on a case-by-case evaluation H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 24/32

25 DRUG SUPPLIER CLASS PROGRAM INFORMATION Pazopanib (VOTRIENT ) Pembrolizumab (KEYTRUDA ) GlaxoSmithKline Merck Canada inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to co-pay based on household income MERCK CARE Oncology Patient Assistance Program Tel: Fax: Enrolment criteria: Metastatic NSCLC with PD-L1 expression ( 50% by validated test) with disease progression on or after platinumcontaining chemotherapy. Patients with EGFR or ALK genomic tumor aberrations with disease progression on prior therapy. Financial assistance available to patients with or without third party insurance coverage. Patients may be asked to co-pay based on household income. Compassionate supply is available based on financial need Infusion coordination for new patients provided at private infusion clinics Bayshore HealthCare. For locations in BC, see: or keytruda@bayshore.ca Assistance offered to Healthcare professionals: PD-L1 status determination is coordinated through the hospital/agency laboratory or through MERCK CARE Oncology Patient Assistance Program. H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 25/32

26 DRUG SUPPLIER CLASS PROGRAM INFORMATION Pemetrexed (ALIMTA ) Pertuzumab (PERJETA ) Pomalidomide (POMALYST ) Lilly Roche Celgene Class I or based on indication ALIMTA Assistance with Reimbursement of Cost (ARC) Program Tel: Fax: Coordination of third party insurance coverage, including WorkSafeBC Based on financial need: o Financial assistance may be available to patients who have third party o Compassionate supply may be available Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with or without third party insurance RevAid program Tel: Fax: Web: Financial assistance is available to all patients with or without third party insurance coverage Compassionate supply may be available for non- funded indications H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 26/32

27 DRUG SUPPLIER CLASS PROGRAM INFORMATION Ponatinib (ICLUSIG ) Paladin funding based on indication ICLUSIG Patient Support Program Tel: Fax: Coordination of third party insurance coverage Ramucirumab (CYRAMZA ) Regorafenib (STIVARGA ) Rituximab (RITUXAN ) Lilly Bayer Roche Class I or based on indication ENCIRCLE Patient Support Program Tel: Fax: Compassionate drug supply may be available Program closed to new enrollment as of May 01, 2017 BTHER4U Patient Support Program Tel: THER4U Fax: THER4U Financial assistance available to all patients with or without third party insurance coverage Compassionate supply may be available Roche Patient Assistance Program (RPAP) Tel: Fax: Infusion coordination provided if required H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 27/32

28 DRUG SUPPLIER CLASS PROGRAM INFORMATION Romidepsin (ISTODAX ) Romiplostim (NPLATE ) Ruxolitinib (JAKAVI ) Siltuximab (SYLVANT ) Celgene Amgen Novartis Janssen ISTODAX Access Program Tel: Fax: Financial assistance available on a case-by-case basis Coordination of third party insurance coverage No compassionate supply available enable Support Program Tel: Fax: No compassionate assistance available The Alliance Patient Support Program Tel : Fax : Janssen Compassionate Use Program Tel: Fax: JanssenMedSci@its.jnj.com Compassionate supply available for those who qualify H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 28/32

29 DRUG SUPPLIER CLASS PROGRAM INFORMATION Sorafenib (NEXAVAR ) Sunitinib (SUTENT ) Temozolomide (TEMODAL ) Temsirolimus (TORISEL ) Bayer Pfizer BTHER4U Patient Support Program Tel: THER4U Fax: THER4U Financial assistance available to all patients with or without third party insurance coverage Compassionate supply may be available Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance may be available on a case-by-case basis Merck Class I Merck Care TM Oncology Tel: Fax: Pfizer Pfizer Liaison Patient Support Program Tel: Fax: Financial assistance may be available on a case-by-case basis H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 29/32

30 DRUG SUPPLIER CLASS PROGRAM INFORMATION Thalidomide (THALOMID ) Tocilizumab (ACTEMRA ) Trametinib (MEKINIST ) Celgene Roche GlaxoSmithKline RevAid program Tel: Fax: Web: Financial assistance is available to all patients with or without third party insurance coverage Compassionate supply may be available for non- funded indications JointEffort program Tel: Fax: inreach Patient Support Program Tel: Fax: Financial assistance is available to patients with or without third party insurance. Patients may be asked to co-pay based on household income Patient must be BRAF-positive Program does not coordinate or cover cost of BRAF testing Home delivery available through BioScript Pharmacy H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 30/32

31 DRUG SUPPLIER CLASS PROGRAM INFORMATION Trastuzumab (HERCEPTIN ) Trastuzumab Emtansine (KADCYLA ) Vandetanib (CAPRELSA ) Roche Roche Sanofi Genzyme Class I or based on indication Roche Patient Assistance Program (RPAP) Tel: Fax: Infusion coordination provided, if required Roche Patient Assistance Program (RPAP) Tel: Fax: Infusion coordination provided, if required CAPRELSA Distribution Program Tel: Fax: Web: Prescribing physicians and pharmacists need to complete a certification process and register with the program in order to enrol patients, prescribe and dispense vandetanib (CAPRELSA ) Financial assistance may be available to patients on a case-by-case basis Reimbursement guidance is available for patients with third party insurance coverage No compassionate supply available H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 31/32

32 DRUG SUPPLIER CLASS PROGRAM INFORMATION Vemurafenib (ZELBORAF ) Venetoclax (VENCLEXTA ) Vismodegib (ERIVEDGE ) Roche AbbVie Roche Roche Patient Assistance Program (RPAP) Tel: Fax: Financial assistance is available to all patients with or without third party insurance Bridging program ceases November 11, 2017 AbbVie Care Program Tel : Fax : Assistance offered : Compassionate supply may be available Roche Patient Assistance Program/ERIVEDGE Pregnancy Prevention Program (RPAP/EPPP) Tel: Fax: Drug can only be dispensed to patients who are registered and meet all conditions of the EPPP. For more information contact EPPP at Date updated: 01 Dec 2017 (updated: fulvestrant, ipilimumab, nivolumab; new: durvalumab, irinotecan liposome) Date created: 17 Oct 2008 H:\Pharm-prov\Provincial DI Coordinator\Protocol\Patient Assistance Programs 32/32

NGO Community Pharmaceutical Care Services in Partnership. Leung Pui Hong, Eugene Pharmacist St. James Settlement Philanthropic Community Pharmacy

NGO Community Pharmaceutical Care Services in Partnership. Leung Pui Hong, Eugene Pharmacist St. James Settlement Philanthropic Community Pharmacy NGO Community Pharmaceutical Care Services in Partnership Leung Pui Hong, Eugene Pharmacist St. James Settlement Philanthropic Community Pharmacy Hong Kong Lion Rock Spirit No Money No Talk No money No

More information

NOVARTIS ONCOLOGY SERVICE REQUEST

NOVARTIS ONCOLOGY SERVICE REQUEST Patient First Name Patient Last Name Patient of Birth NOVARTIS ONCOLOGY SERVICE REQUEST FORM FOR PATIENT SUPPORT For more information, please call 1-800-282-7630 from 9:00 am to 8:00 pm ET, Monday through

More information

NOVARTIS ONCOLOGY SERVICE REQUEST

NOVARTIS ONCOLOGY SERVICE REQUEST NOVARTIS ONCOLOGY SERVICE REQUEST FORM (CONT) Patient First Name Patient Last Name Patient of Birth NOVARTIS ONCOLOGY SERVICE REQUEST 5. PRESCRIPTION INFORMATION (TO BE COMPLETED BY PRESCRIBER) FORM FOR

More information

Compliance Training. Hazardous Drug Safety

Compliance Training. Hazardous Drug Safety Compliance Training A If hazardous drugs, as they are defined by OSHA, are administered for any therapeutic purpose, the employer must develop and implement a and Health Plan (HDSHP). The purpose for which

More information

PROVIDER NEWSLETTER. Table of Contents. UniCare Health Plan of West Virginia, Inc. June Reimbursement Policy

PROVIDER NEWSLETTER. Table of Contents.   UniCare Health Plan of West Virginia, Inc. June Reimbursement Policy www.unicare.com June 2018 PROVIDER NEWSLETTER UniCare Health Plan of West Virginia, Inc. Table of Contents Provider surveys Page 2 Providing whole person care Page 2 Complex Case Management program Page

More information

Pfizer Patient Assistance & Insurance Support Programs: Enrollment Form for Group B Medicines

Pfizer Patient Assistance & Insurance Support Programs: Enrollment Form for Group B Medicines Pfizer Patient Assistance & Insurance Support Programs: Enrollment Form for Group B Medicines This enrollment form is for patients who would like to apply to receive any of the Group B medicines found

More information

Ontario Public Drug Programs

Ontario Public Drug Programs Chapter 3 Section 3.09 Ministry of Health and Long-Term Care Ontario Public Drug Programs Chapter 3 VFM Section 3.09 1.0 Summary About four million Ontarians receive drug coverage through the Ontario Public

More information

Enrollment Application for the Novartis Patient Assistance Foundation, Inc.

Enrollment Application for the Novartis Patient Assistance Foundation, Inc. Novartis Patient Assistance Foundation, Inc. Enrollment Application for the Novartis Patient Assistance Foundation, Inc. Information P.O. Box 52029, Phoenix, AZ 85072-2029 Phone: 1-800-277-2254 Fax: 1-855-817-2711

More information

Medicare Advantage 2016 Precertification Requirements

Medicare Advantage 2016 Precertification Requirements Medicare Advantage 2016 Precertification Requirements (Effective for January 1, 2016 to December 31, 2016) The following Medicare Advantage plans require precertification i from in network providers. Call

More information

2017 SAFETY AUDIT PLAN

2017 SAFETY AUDIT PLAN 2017 SAFETY AUDIT PLAN Using the Safety Audit Plan: Purpose The Safety Audit Plan is intended to provide practices with a checklist of tasks that should be completed to fully implement safety policies,

More information

Table of Contents. Medicaid: Amerivantage: Reimbursement Policy: April 2018

Table of Contents. Medicaid: Amerivantage: Reimbursement Policy: April 2018 Provider Newsletter Amerigroup Washington, Inc. https://providers.amerigroup.com/ Medicaid providers: 1-800-454-3730 Medicare providers: 1-866-805-4589 April 2018 Table of Contents Medicaid: Right care

More information

Executive Summary pgs. 4-9 Background pgs. 4-6 REMS Drugs pgs. 7-8 Specialty Drug Distribution pg. 9

Executive Summary pgs. 4-9 Background pgs. 4-6 REMS Drugs pgs. 7-8 Specialty Drug Distribution pg. 9 Executive Summary pgs. 4-9 Background pgs. 4-6 REMS Drugs pgs. 7-8 Specialty Drug Distribution pg. 9 Specialty Pharmacies - pgs. 10-52 AcariaHealth pgs. 10-11 Accredo Health/CuraScript pgs. 12-15 Amber

More information

Breast Health. Topic Index. General Education. Breast Anatomy Graphics. Breast Imaging Procedures. Mammography Forms and Letters.

Breast Health. Topic Index. General Education. Breast Anatomy Graphics. Breast Imaging Procedures. Mammography Forms and Letters. Topic Index Breast Health Topic Index General Education Antiperspirants and Breast Cancer; 0101 Bra Fitting; 0102 Breast Cancer Facts; 0103 Breast Cancer Misconceptions and Facts; 0104 Breast Cancer Statistics;

More information

Specialty Pharmacy How is Traditional Pharmacy Practice Positioned

Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Nick Calla Vice President, Industry Relations Cardinal Health Specialty Solutions August 19, 2016 Today s Learning Objectives Understand

More information

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed

More information

DEFINING CANADIAN CERTIFICATION FOR ONCOLOGY PHARMACISTS

DEFINING CANADIAN CERTIFICATION FOR ONCOLOGY PHARMACISTS DISCLOSURES DEFINING CANADIAN CERTIFICATION FOR ONCOLOGY PHARMACISTS Flay Charbonneau Mark Pasetka 22 April, 2017 Canadian Association of Pharmacy in Oncology Conference Banff, Alberta Flay Charbonneau

More information

Jennifer Clements, Director of Provider Operations

Jennifer Clements, Director of Provider Operations To: From: SCFHP Providers Jennifer Clements, Director of Provider Operations Date: 01/19/2016 Subject: Prior Authorization Process and Turnaround Times Dear Provider: Santa Clara Family Health Plan (SCFHP)

More information

Patient and Citizen Engagement in HTA Decision Making. E4 Panel session, CADTH Symposium, May7th, 2013

Patient and Citizen Engagement in HTA Decision Making. E4 Panel session, CADTH Symposium, May7th, 2013 Patient and Citizen Engagement in HTA Decision Making E4 Panel session, CADTH Symposium, May7th, 2013 1 Agenda Moderation o Paul Oh Patient perspective o Durhane Wong-Reiger Citizen perspective o Janet

More information

July Provider and Clinical Updates. An Update for West Virginia Family Health Providers and Clinicians

July Provider and Clinical Updates. An Update for West Virginia Family Health Providers and Clinicians July 2018 An Update for West Virginia Family Health Providers and Clinicians Provider and Clinical Updates National Correct Coding Initiative (NCCI) Edits...... 2-3 LabCorp is Preferred Provider for Outpatient

More information

Overall Learning Objectives How large is the specialty pharmaceutical market? Drug Trends Source: CVS Caremark 2013 Drug Trend Focus Report

Overall Learning Objectives How large is the specialty pharmaceutical market? Drug Trends Source: CVS Caremark 2013 Drug Trend Focus Report What s So Special About Specialty Pharmacies? Overview and Role of Pharmacists and Pharmacy Technicians Implementation of a Specialty Pharmacy Program Overall Learning Objectives For Pharmacists and Pharmacy

More information

Round Table Discussion: Shared Views and Perspectives on Outsourcing

Round Table Discussion: Shared Views and Perspectives on Outsourcing Round Table Discussion: Shared Views and Perspectives on Outsourcing IQ Drug Metabolism Leadership Group Pharmaceutical Industry Benchmarking CPSA Shanghai, April 17th, 2018 www.iqconsortium.org IQ: Collaboration

More information

DOING THE RIGHT THING AND DOING THINGS RIGHT

DOING THE RIGHT THING AND DOING THINGS RIGHT 2013 EUROPEAN MEETING OF ISMPP DOING THE RIGHT THING AND DOING THINGS RIGHT 22 23 January, 2013 st paul s 200 aldersgate london, UK Why Exhibit at, and Sponsor the European Meeting? Sponsors and exhibitors

More information

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed

More information

FEBRUARY 4 TH, 2017 PROGRAM CHAIRS REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA RESERVE YOUR SPACE TODAY! PLEASE CONTACT:

FEBRUARY 4 TH, 2017 PROGRAM CHAIRS REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA RESERVE YOUR SPACE TODAY! PLEASE CONTACT: FEBRUARY 4 TH, 2017 REAL INTERCONTINENTAL HOTEL, SAN JOSE, COSTA RICA PROGRAM CHAIRS Dr. Carlos Eduardo Zúñiga Orlich Medical Oncologist President, Costa Rican Association of Medical Oncology (ACOMED)

More information

Since 2005, 10 oral chemotherapy medications have

Since 2005, 10 oral chemotherapy medications have Are Patients on Oral Chemotherapy in Your Practice Setting Safe? Mendy Moody, RN, MSN, OCN, and Joyce Jackowski, MS, FNP-BC, AOCNP The use of oral chemotherapy is expected to more than double in the next

More information

The Catholic Marienkrankenhaus nonprofit company with limited liability charges the following fees starting January 1st 2016:

The Catholic Marienkrankenhaus nonprofit company with limited liability charges the following fees starting January 1st 2016: The Catholic Marienkrankenhaus nonprofit company with limited liability charges the following fees starting January 1st 2016: 1. Diagnosis Related Groups (DRGs) according to 17b KHG Fees for general entirely

More information

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION)

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION) THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (LATIN AMERICA EDITION) Feedback from 58 Latin-American patient groups PUBLISHED JUNE 2016 Que las Compañias Farmacéuticas tengan relación

More information

Ref: FOI/CAD/ID August Freedom of Information Act 2000

Ref: FOI/CAD/ID August Freedom of Information Act 2000 Ref: FOI/CAD/ID 3437 24 August 2016 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act

More information

Objectives. Hospital Pharmacy Strategies for REMS. Evolution of FDA Drug Safety Programs. REMS: Definition. Evolution of FDA Drug Safety Programs

Objectives. Hospital Pharmacy Strategies for REMS. Evolution of FDA Drug Safety Programs. REMS: Definition. Evolution of FDA Drug Safety Programs Objectives Hospital Pharmacy Strategies for REMS SCSHP Fall Meeting October 28, 2010 John Pearson, PharmD, BCNSP, BCPS Manager, Pharmacy Clinical Services Greenville Hospital System University Medical

More information

ICMJE Form for Disclosure of Potential Conflicts of Interest

ICMJE Form for Disclosure of Potential Conflicts of Interest Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed

More information

NewsBrief. AvMed Network. What's News. Administrative Updates. Health & Medical. AvMed's 2016 Achievement Highlights. Be Fluent

NewsBrief. AvMed Network. What's News. Administrative Updates. Health & Medical. AvMed's 2016 Achievement Highlights. Be Fluent AvMed Network NewsBrief Winter Issue February 2017 What's News AvMed's 2016 Achievement Highlights Administrative Updates Be Fluent Health & Medical J-Codes Requiring Prior Authorization A quarterly publication

More information

LEMTRADA Services Form

LEMTRADA Services Form For Patients to Complete LEMTRADA Services Form Instructions for healthcare providers enrolling patients in One to One To enroll in One to One Support Services for LEMTRADA (alemtuzumab), you and your

More information

Patient Assistance and Financial Access for Immuno-Oncology

Patient Assistance and Financial Access for Immuno-Oncology Patient Assistance and Financial Access for Immuno-Oncology Charles Lynch Program Coordinator of Oncology Medication Assistance Program; Smilow Cancer Hospital at Yale New Haven January 21,2016 12-1 p.m.

More information

Determining staffing needs can be challenging

Determining staffing needs can be challenging Downloaded by faranakhaghighi@sbcglobal.net on date 02 07 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please

More information

2018 Integrated Managed Care

2018 Integrated Managed Care Prescriptions, Pharmacy, Drugs Please visit CHPW's searchable formulary (http://chpw.org/formembers/pharmacy/apple-healthformulary) to look up current formulary status of medications Refer to searchable

More information

2018 Plan Year State Employees Prescription Drug Plan

2018 Plan Year State Employees Prescription Drug Plan 2018 Plan Year State Employees Prescription Drug Plan Welcome to CVS Caremark We manage your prescription benefits like your health insurance company manages your medical benefits. That means helping you

More information

Number of Persons in your Household 1 $60,300 4 $123,000 2 $81,200 5 $143,900 3 $102,100 6 $164,800

Number of Persons in your Household 1 $60,300 4 $123,000 2 $81,200 5 $143,900 3 $102,100 6 $164,800 The Lilly Cares Foundation, Inc. ("Lilly Cares"), a nonprofit organization, offers a patient assistance program to assist qualifying patients in obtaining certain Lilly medications at no cost. This enrollment

More information

Sponsor & Exhibitor Prospectus

Sponsor & Exhibitor Prospectus 23rd CONFERENCE Improving the Quality, Effectiveness, & Efficiency of Cancer Care March 22 24, 2018 Rosen Shingle Creek Orlando, Florida 201 Sponsor & Exhibitor Prospectus Exhibition Hall Dates March 22

More information

NeedyMeds

NeedyMeds NeedyMeds www.needymeds.org Find help with the cost of medicine Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.

More information

HHr Health and Human Rights Journal

HHr Health and Human Rights Journal HHr Health and Human Rights Journal Revisiting Health Rights Litigation and Access to Medications in Costa Rica: Preliminary Evidence from the Cochrane Collaboration Reform olman rodríguez loaiza, sigrid

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal (STA)

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal (STA) NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Single Technology Appraisal (STA) Vedolizumab for treating moderately to serverely Provisional matrix of consultees and commentators Manufacturers/sponsors

More information

Conflict of Interest Disclosure Form

Conflict of Interest Disclosure Form I n s t i t u t i o n o f t h e U E M S a i s b l NAME : Florian Lordick AFFILIATION: University Cancer Center Leipzig organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement

More information

ACCREDITATION PROGRAMME FOR ORAL SYSTEMIC ANTI-CANCER THERAPIES (SACT) COUNSELLING BY PHARMACY STAFF

ACCREDITATION PROGRAMME FOR ORAL SYSTEMIC ANTI-CANCER THERAPIES (SACT) COUNSELLING BY PHARMACY STAFF - ACCREDITATION PROGRAMME FOR ORAL SYSTEMIC ANTI-CANCER THERAPIES (SACT) COUNSELLING BY PHARMACY STAFF 1 Scope of Document... 3 2 Background... 3 3 Outline... 4 4 Accreditation Pathway... 6 5 Suggested

More information

Corporate Profile. December 2017

Corporate Profile. December 2017 Corporate Profile December 2017 Our corporate overview Pharmaceutical Distribution Largest pharmaceutical distributor in Canada, handling ~40% of all retail & hospital volume Ensuring patients have nextday

More information

Pfizer Patient Assistance Program

Pfizer Patient Assistance Program Pfizer Patient Assistance Program Application for Patients This application form is for patients who would like to apply to receive INFLECTRA (infliximab-dyyb) for Injection, NIVESTYM (filgrastim-aafi)

More information

RMI Researched Medicines Industry Association

RMI Researched Medicines Industry Association RMI Researched Medicines Industry Association Submission to: Medsafe On the: Proposed Clinical Trials Guidelines 30 November 2009 Contact Kevin Sheehy, Scientific and Technical Manager RMI, Level 8, 86

More information

updatesm December 2016 Professional Injectable and Vaccine Fee Schedule updates effective January 1, 2017 page 8

updatesm December 2016 Professional Injectable and Vaccine Fee Schedule updates effective January 1, 2017 page 8 updatesm December 2016 2017 out-of-pocket maximums for commercial HMO, POS, and PPO members page 7 Professional Injectable and Vaccine Fee Schedule updates effective January 1, 2017 page 8 Our prescription

More information

Australian Biomedical & Healthcare

Australian Biomedical & Healthcare Australian Biomedical & Healthcare A Wealth of Investment Opportunities Sam Guthrie Senior Trade Commissioner Australian Trade & Investment Commission Why Australia 1 4 th largest economy in the Asia region

More information

IMPORTANT CONTACTS FOR AUTHORIZATIONS SUBMITTED TO THE HEALTH PLAN

IMPORTANT CONTACTS FOR AUTHORIZATIONS SUBMITTED TO THE HEALTH PLAN For prescription drug requirements, see plan formularies. See Separate List for Adventist Health Systems & Rosen Employees. General Information These requirements are administered by Florida Hospital Care

More information

Managing Adherence with a Mobile Population Leslie Yendro, RN

Managing Adherence with a Mobile Population Leslie Yendro, RN Managing Adherence with a Mobile Population Leslie Yendro, RN Vice President, Business Development Avella Specialty Pharmacy Objectives Discuss the impact of non-adherence on patient outcomes. Review various

More information

Briefly. Improving quality of care. In this issue. Geisinger Health Plan. Briefly is also available online at thehealthplan.com.

Briefly. Improving quality of care. In this issue. Geisinger Health Plan. Briefly is also available online at thehealthplan.com. Geisinger Health Plan Briefly December 2012 A Publication for Providers and Office Personnel In this issue 2 Improving quality of care Improving quality of care 3 NIA update Geisinger Gold update 4 Medical

More information

Boston University Expert Review Meeting on the Evaluation of Novartis Access

Boston University Expert Review Meeting on the Evaluation of Novartis Access Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie

More information

IMPROVING THE AVAILABILITY OF MEDICINES FOR PATIENTS IN WALES TOP-UP PAYMENTS IMPLEMENTATION GROUP REPORT

IMPROVING THE AVAILABILITY OF MEDICINES FOR PATIENTS IN WALES TOP-UP PAYMENTS IMPLEMENTATION GROUP REPORT IMPROVING THE AVAILABILITY OF MEDICINES FOR PATIENTS IN WALES TOP-UP PAYMENTS IMPLEMENTATION GROUP REPORT February 2011 Contents Foreword...1 1 NHS principles...2 2 Terminology...2 3 Access to medicines

More information

Oncology Management: The Aetna Experience in Personalized, Value-Based Care

Oncology Management: The Aetna Experience in Personalized, Value-Based Care Oncology Management: The Aetna Experience in Personalized, Value-Based Care Wednesday, April 9, 2014 1:00 2:30 Eastern time 12:00 1:30 Central time 11:00 12:30 Mountain time 10:00 11:30 Pacific time Ira

More information

EXCLUSIVE CARE SUMMARY OF COVERED BENEFITS Select Medicare Eligible Supplement Plan

EXCLUSIVE CARE SUMMARY OF COVERED BENEFITS Select Medicare Eligible Supplement Plan 2018 EXCLUSIVE CARE SUMMARY OF COVERED BENEFITS Select Medicare Eligible Supplement Plan Summary Table of Benefits Select Medicare Supplement Plan PLAN REIMBURSEMENT METHOD DEDUCTIBLE - Individual Medicare

More information

Reimbursement in Europe. Tues 5 th Dec 11.00am

Reimbursement in Europe. Tues 5 th Dec 11.00am Reimbursement in Europe Tues 5 th Dec 11.00am Overview of Session 11.00 Introduction to Reimbursement In Europe Session James Rose 11.15 The EU Health MAPPS Project Erwin Heeneman 11.30 Supporting start-ups

More information

VENCLEXTA PATIENT SUPPORT SERVICES

VENCLEXTA PATIENT SUPPORT SERVICES VENCLEXTA PATIENT SUPPORT SERVICES Models shown are not actual patients or health care professionals. Indication VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)

More information

ABOUT THE REPORT. About the 3-Month Report

ABOUT THE REPORT. About the 3-Month Report THE DIGEST OF BIOTECH JOB TRENDS IN MASSACHUSET TS QUARTERLY LIFE SCIENCES JOB MARKET REPORT (Abbreviated) Q2 2018 ABOUT THE REPORT About the 3-Month Report MassBioEd produces a Quarterly on biopharmaceutical

More information

Market With Innovation

Market With Innovation Leading The Specialty Market With Innovation Alan Lotvin, M.D. Executive Vice President, CVS/specialty Agenda Specialty Market Overview Performance Highlights Reinventing Specialty Pharmacy Well Positioned

More information

Irvine Unified School District ASO PPO /50

Irvine Unified School District ASO PPO /50 An Independent member of the Blue Shield Association Irvine Unified School District ASO PPO 500 90/50 Benefit Summary (For groups of 300 and above) (Uniform Health Plan Benefits and Coverage Matrix) THIS

More information

Sponsor & Exhibitor Prospectus

Sponsor & Exhibitor Prospectus March 21 23, Rosen Shingle Creek Orlando, Florida Sponsor & Exhibitor Prospectus Exhibition Hall Dates March 21 22, 2018 Early Bird Discount Save when you reserve space by Friday, November 30, 2018 Application

More information

Application Form Instructions

Application Form Instructions The Lilly Cares Foundation, Inc., a private operating foundation, offers the Lilly Cares patient assistance program to help qualifying people get selected Lilly medications. What products are included?

More information

October 30 November 2, 2014 Loews Royal Pacific Hotel at Universal Orlando, FL

October 30 November 2, 2014 Loews Royal Pacific Hotel at Universal Orlando, FL EXHIBIT & SPONSORSHIP PROSPECTUS A CE Event for Advanced Practitioners October 30 November 2, 2014 Loews Royal Pacific Hotel at Universal Orlando, FL This CE/CME/CEU accredited conference is jointly sponsored

More information

Licensed Pharmacy Technicians Scope of Practice

Licensed Pharmacy Technicians Scope of Practice Licensed s Scope of Practice Adapted from: Request for Regulation of s Approved by Council April 24, 2015 DEFINITIONS In this policy: Act means The Pharmacy and Pharmacy Disciplines Act means an unregulated

More information

High Deductible Health Plan (HDHP)

High Deductible Health Plan (HDHP) High Deductible Health Plan (HDHP) BeneFIts Summary Effective July 1, 2012 or October 1, 2012 Benefit Highlights How The Plan Works...1 Summary Of Benefits...4 Special Programs...7 Approval Of Care At

More information

Multiple Sclerosis in Practice. An Expert Commentary with Fred D. Lublin, MD, FAAN. A Clinical Context Report

Multiple Sclerosis in Practice. An Expert Commentary with Fred D. Lublin, MD, FAAN. A Clinical Context Report Multiple Sclerosis in Practice An Expert Commentary with Fred D. Lublin, MD, FAAN A Clinical Context Report Clinical Context: Multiple Sclerosis in Practice Expert Commentary Jointly Sponsored by: and

More information

Prescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors

Prescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors Publication Report Prescribing & Medicines: Reimbursement and remuneration paid to dispensing contractors Calendar and financial years 2007-2012 Publication date 25 September 2012 A National Statistics

More information

Oncology Pharmacy Services

Oncology Pharmacy Services Oncology Pharmacy Services Your partner in patient-centered care Supporting you and your patients You want to focus on patient care, not paperwork. So you need an oncology pharmacy that does more than

More information

Home Infusion Payment Policy

Home Infusion Payment Policy Home Infusion Payment Policy Policy Blue Cross Blue Shield of Massachusetts (Blue Cross)* reimburses contracted providers for covered, medically necessary home infusion services. General Benefit Information

More information

D DRUG DISTRIBUTION SYSTEMS

D DRUG DISTRIBUTION SYSTEMS D DRUG DISTRIBUTION SYSTEMS JANET HARDING ORAL MEDICATION SYSTEMS Drug distribution systems in the hospital setting should ideally prevent medication errors from occurring. When errors do occur, the system

More information

YOUR TREATMENT NEEDS ARE OUR PRIORITY

YOUR TREATMENT NEEDS ARE OUR PRIORITY YOUR TREATMENT NEEDS ARE OUR PRIORITY PTC CaresTM is your patient support program that s dedicated to helping you gain access to therapy. See inside to learn more Call 1-844-4PTC-CARES 8 AM - 8 PM EST

More information

European HTA collaboration Current status, future plans and relevance for the Netherlands

European HTA collaboration Current status, future plans and relevance for the Netherlands European HTA collaboration Current status, future plans and relevance for the Netherlands Wim Goettsch EUnetHTA JA3 Directorate, Zorginstituut Nederland Bruggink, Almere, 7-3-2018 Outline HTA and market

More information

Cotiviti Approved Issues List as of April 27, 2017

Cotiviti Approved Issues List as of April 27, 2017 Cotiviti Approved Issues List as of April 27, 2017 Ambulatory Surgery Center (ASC); Outpatient Hospital 23 Inpatient Hospital 25 Inpatient Hospital; Inpatient Psychiatric Facility 27 Inpatient; Outpatient;

More information

Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project. Chris Chinn VP and Head of RWE

Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project. Chris Chinn VP and Head of RWE Pragmatic Trials: how early in drug development? Salford Lung Studies & IMI GetReal Project Chris Chinn VP and Head of RWE The need for Pragmatic Clinical Trials Healthcare decision makers are searching

More information

NeedyMeds

NeedyMeds NeedyMeds www.needymeds.org Find help with the cost of medicine Thank you for downloading this patient assistance document from NeedyMeds. We hope this program will help you get the medicine you need.

More information

DISPENSING BY REGISTERED NURSES (RNs) EMPLOYED WITHIN REGIONAL HEALTH AUTHORITIES (RHAs)

DISPENSING BY REGISTERED NURSES (RNs) EMPLOYED WITHIN REGIONAL HEALTH AUTHORITIES (RHAs) 2017 DISPENSING BY REGISTERED NURSES (RNs) EMPLOYED WITHIN REGIONAL HEALTH AUTHORITIES (RHAs) This Interpretive Document was approved by ARNNL Council in 2017 and replaces Dispensing by Registered Nurses

More information

NY EPO OA 1-09 v Page 1

NY EPO OA 1-09 v Page 1 PLAN FEATURES Deductible (per calendar year) Member Coinsurance (applies to all expenses unless otherwise stated) Maximum Out-of-Pocket Limit (per calendar year) Lifetime Maximum (per member lifetime)

More information

NHS HDL (2002) 22 abcdefghijklm

NHS HDL (2002) 22 abcdefghijklm NHS HDL (2002) 22 abcdefghijklm Health Department Dear Colleague SAFE ADMINISTRATION OF INTRATHECAL CYTOTOXIC CHEMOTHERAPY Purpose This circular provides Guidance on the Safe Administration of Intrathecal

More information

Application Form Instructions

Application Form Instructions Lilly Cares Foundation Patient Assistance Program PO Box 13185 La Jolla, CA 92039 1-800-545-6962 Fax: (844) 431-6650 www.lillycares.com The Lilly Cares Foundation, Inc., a separate nonprofit foundation,

More information

Dec LILLE, France. 7 th. edition. A 360 approach to source early-stage innovations in Life Sciences. Organised by: In collaboration with:

Dec LILLE, France. 7 th. edition. A 360 approach to source early-stage innovations in Life Sciences. Organised by: In collaboration with: LILLE, France 4 th & 5 th Dec. 2018 7 th edition A 360 approach to source early-stage innovations in Life Sciences Organised by: In collaboration with: BioFIT at a glance BioFIT is the leading partnering

More information

Over the past 10 years, treatment options

Over the past 10 years, treatment options This special feature provides information for patients about oral medications for the treatment of multiple myeloma. The main article discusses the progress that has been made in the treatment of multiple

More information

3/16/2017. A Tale of Two Specialty Pharmacies: Novel Models for Technician Incorporation. Objectives. What is Specialty Pharmacy?

3/16/2017. A Tale of Two Specialty Pharmacies: Novel Models for Technician Incorporation. Objectives. What is Specialty Pharmacy? A Tale of Two Specialty Pharmacies: Novel Models for Technician Incorporation Disclosures The speakers have no actual or potential conflict of interest to the content of this presentation. Renee Advincula,

More information

Blue Shield of California

Blue Shield of California An independent member of the Blue Shield Association City of San Jose Custom ASO PPO 100 90/70 Active Employees Benefit Summary (For groups of 300 and above) (Uniform Health Plan Benefits and Coverage

More information

Administrators. Medical Directors. 61% The negative impact on our hospital-based program s. 44% We will need to consider the most appropriate or most

Administrators. Medical Directors. 61% The negative impact on our hospital-based program s. 44% We will need to consider the most appropriate or most 2016 This annual survey, which began in 2009, provides key insight into nationwide developments in the business of cancer care. To better capture information from its multidisciplinary membership, this

More information

On Pins & Needles: Caregivers of Adults with Mental Illness

On Pins & Needles: Caregivers of Adults with Mental Illness On Pins & Needles: Caregivers of Adults with Mental Illness Rick Greene, National Alliance for Caregiving International Carers Conference, Adelaide, Australia 1 Report Sponsors This research was made possible

More information

Provincial/Territorial Perspective Drug Shortages: BC and Beyond

Provincial/Territorial Perspective Drug Shortages: BC and Beyond Provincial/Territorial Perspective Drug Shortages: BC and Beyond Elaine Chong, British Columbia Ministry of Health 2017 CADTH Symposium April 24, 2017 Overview Collaborative Context Provincial/Territorial

More information

All Wales Continuous Subcutaneous Infusion Medication Administration Record AWMR10

All Wales Continuous Subcutaneous Infusion Medication Administration Record AWMR10 All Wales Continuous Subcutaneous Infusion ication Administration Record AWMR0 Why do we need a standardised chart? The All Wales Palliative Care Pharmacists Group (AWPCPG) collated information on how

More information

Crawley CCG LCS Dec 15 Final

Crawley CCG LCS Dec 15 Final Crawley CCG LCS Dec 15 Final Crawley CCG Service Proposal for the inclusion of administration and monitoring of Denosumab 60mg Injection (Prolia )in GP Practices under a Locally Commissioned Service February

More information

CASE-BY-CASE REVIEW PROGRAM (CBCRP) CASE-BY-CASE REVIEW POLICY FOR CANCER DRUGS

CASE-BY-CASE REVIEW PROGRAM (CBCRP) CASE-BY-CASE REVIEW POLICY FOR CANCER DRUGS CASE-BY-CASE REVIEW PROGRAM (CBCRP) CASE-BY-CASE REVIEW POLICY FOR CANCER DRUGS Version: 3.0 Effective Date: October 2013 Replaces Policy: Case-by-Case Review Policy for Cancer Drugs, November 8, 2011

More information

Patient Section All fields are required. Please print clearly and complete all information.

Patient Section All fields are required. Please print clearly and complete all information. Lilly Cares Foundation Patient Assistance Program PO Box 13185 La Jolla, CA 92039 Phone: 1-800-545-6962 Fax: 1-844-431-6650 www.lillycares.com Patient Section All fields are required. Please print clearly

More information

DRUG COVERAGE PEARLS FOR THE HOSPITAL PHARMACIST. Souzi Badr BScPhm, PharmD, ACPR

DRUG COVERAGE PEARLS FOR THE HOSPITAL PHARMACIST. Souzi Badr BScPhm, PharmD, ACPR DRUG COVERAGE PEARLS FOR THE HOSPITAL PHARMACIST Souzi Badr BScPhm, PharmD, ACPR Disclosures Presenter Disclosure I have no current or past relationships with commercial entities I have received no speaker

More information

Chapter 52. Board of Pharmacy.

Chapter 52. Board of Pharmacy. Chapter 52. Board of Pharmacy. (Words in boldface and underlined indicate language being added; words [CAPITALIZED AND BRACKETED] indicate language being deleted. Complete new sections are not in boldface

More information

247 CMR: BOARD OF REGISTRATION IN PHARMACY

247 CMR: BOARD OF REGISTRATION IN PHARMACY 247 CMR 9.00: CODE OF PROFESSIONAL CONDUCT; PROFESSIONAL STANDARDS FOR REGISTERED PHARMACISTS, PHARMACIES AND PHARMACY DEPART- MENTS Section 9.01: Code of Professional Conduct for Registered Pharmacists,

More information

Office of Inspector General (OIG) Medicare Compliance Reviews

Office of Inspector General (OIG) Medicare Compliance Reviews Office of Inspector General (OIG) Medicare Compliance Reviews HCCA 2014 Compliance Institute, 4:30-5:30 Facilitators Steve Gillis, Director, Compliance Coding Billing & Audit Partners HealthCare Boston,

More information

Office of Inspector General (OIG) Medicare Compliance Reviews

Office of Inspector General (OIG) Medicare Compliance Reviews Office of Inspector General (OIG) Medicare Compliance Reviews HCCA 2014 Compliance Institute, 4:30-5:30 Facilitators Steve Gillis, Director, Compliance Coding Billing & Audit Partners HealthCare Boston,

More information

Voice Mail Message Method Preferred Phone No Message. . Sign. *Relationship to Patient. Insurance Phone. Allergies Current Medications POS NEG

Voice Mail Message Method Preferred Phone No Message.  . Sign. *Relationship to Patient. Insurance Phone. Allergies Current Medications POS NEG SECTION 1 Patient Information Patient (First, MI, Last) Street Address City State ZIP Code DOB (mm/dd/yyyy) Preferred Phone Best Hours to Call Voice Mail Message Method Preferred Phone No Message Email

More information

Skilled nursing facility visits

Skilled nursing facility visits Modified Premier HMO 20 Non Union This Summary of Benefits is a brief overview of your plan's benefits only. For more detailed information about the benefits in your plan, please refer to your Certificate

More information

Pfizer Patient Assistance Program: Instructions for Group D Enrollment Form

Pfizer Patient Assistance Program: Instructions for Group D Enrollment Form Pfizer Patient Assistance Program: Instructions for Group D Enrollment Form This enrollment form is for patients who would like to apply to receive Lyrica (pregabalin) or Lyrica CR (pregabalin) extended

More information

PCAB Compounding Accreditation Accreditation Summary

PCAB Compounding Accreditation Accreditation Summary PCAB Compounding Accreditation Accreditation Summary McGuff Compounding Pharmacy Services, Inc Santa Ana, California compounding pharmacy 2921 W. MacArthur Blvd., Ste.142 Santa Ana, CA 92704 Telephone:877-444-1133

More information

pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation

pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation Ibrutinib (Imbruvica) for Mantle Cell Lymphoma Lymphoma Foundation Canada July

More information